Open AccessRepetitive response to gemcitabine that led to curative resection in cholangiocarcinoma
Author(s) -
Seong Hun Kim,
In Hee Kim,
Sang Wook Kim,
Seungok Lee
Publication year - 2009
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.15.4593
Subject(s) - gemcitabine , medicine , intrahepatic cholangiocarcinoma , oncology , antimetabolite , chemotherapy , surgical resection , neoadjuvant therapy , deoxycytidine , prospective cohort study , resection , surgery , gastroenterology , cancer , breast cancer
This study reports a case of unresectable intrahepatic mass-forming cholangiocarcinoma which showed a dramatic response to gemcitabine that led to curative resection and a long-term survival of more than five years. Six and five cycles of gemcitabine monotherapy were administered separately over a three-year period and a radical excision was performed at 4.5 years after diagnosis. This case indicates the role of gemcitabine as a neoadjuvant chemotherapeutic agent for cholangiocarcinoma and guarantees a randomized controlled prospective study.